<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>373</serviceExecutionTime><Drug id="59924"><DrugName>vistusertib</DrugName><DrugNamesKey><Name id="43062998">vistusertib</Name></DrugNamesKey><DrugSynonyms><Name><Value>KU-0063794</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>mTOR inhibitors (cancer), AstraZeneca</Value></Name><Name><Value>KU-63794</Value></Name><Name><Value>mTOR inhibitors (cancer), KuDOS</Value></Name><Name><Value>AZD-2014</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>vistusertib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>1009298-59-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="27874">KuDOS Pharmaceuticals Ltd</CompanyOriginator><CompaniesSecondary><Company id="14190">AstraZeneca plc</Company><Company id="27874">KuDOS Pharmaceuticals Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="59924" type="Drug"><TargetEntity id="682001" type="siDrug">Vistusertib</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="27874" type="Company"><TargetEntity id="4297997017" type="organizationId">KuDOS Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="1261" type="ciIndication"><TargetEntity id="10041056" type="MEDDRA"/><TargetEntity id="D055752" type="MeSH"/><TargetEntity id="70573" type="ORPHANET"/><TargetEntity id="-1257831198" type="omicsDisease"/><TargetEntity id="614" type="siCondition"/></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="1749" type="ciIndication"><TargetEntity id="C83.3" type="ICD10"/><TargetEntity id="10012818" type="MEDDRA"/><TargetEntity id="D016403" type="MeSH"/><TargetEntity id="544" type="ORPHANET"/><TargetEntity id="-308083648" type="omicsDisease"/><TargetEntity id="1741" type="siCondition"/></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"/><TargetEntity id="10060862" type="MEDDRA"/><TargetEntity id="D011471" type="MeSH"/><TargetEntity id="-405461207" type="omicsDisease"/><TargetEntity id="637" type="siCondition"/><TargetEntity id="5083" type="siCondition"/></SourceEntity><SourceEntity id="2802" type="ciIndication"><TargetEntity id="10027191" type="MEDDRA"/><TargetEntity id="D008579" type="MeSH"/><TargetEntity id="2495" type="ORPHANET"/><TargetEntity id="-54797992" type="omicsDisease"/><TargetEntity id="1466" type="siCondition"/></SourceEntity><SourceEntity id="3521" type="ciIndication"><TargetEntity id="Q85.01" type="ICD10"/><TargetEntity id="D009456" type="MeSH"/><TargetEntity id="636" type="ORPHANET"/><TargetEntity id="-1668622175" type="omicsDisease"/><TargetEntity id="2661" type="siCondition"/></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"/><TargetEntity id="589" type="siCondition"/></SourceEntity><SourceEntity id="3666" type="ciIndication"><TargetEntity id="10063916" type="MEDDRA"/><TargetEntity id="647" type="siCondition"/></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"/><TargetEntity id="3229" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="76090" type="Action"><TargetEntity id="3739" type="Mechanism">mTOR Complex 1 (mTORC1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="76096" type="Action"><TargetEntity id="3740" type="Mechanism">mTOR Complex 2 (mTORC2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-13173" type="ciTarget"><TargetEntity id="123271" type="siTarget">mTOR complex 1</TargetEntity></SourceEntity><SourceEntity id="PTGT-13174" type="ciTarget"><TargetEntity id="123281" type="siTarget">mTOR complex 2</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1261">Small-cell lung cancer</Indication><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="1749">Diffuse large B-cell lymphoma</Indication><Indication id="276">Prostate tumor</Indication><Indication id="2802">Meningioma</Indication><Indication id="3521">Neurofibromatosis type I</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3666">Metastatic stomach cancer</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="4250">Metastatic renal cell carcinoma</Indication><Indication id="651">Cancer</Indication><Indication id="763">Nerve tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="76096">mTOR complex 2 inhibitor</Action><Action id="76090">mTOR complex 1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="7293">Synergist</Action><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-02-12T10:14:22.000Z</LastModificationDate><ChangeDateLast>2019-01-08T00:00:00.000Z</ChangeDateLast><AddedDate>2008-04-22T12:31:49.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;, following its acquisition of  &lt;ulink linkID="27874" linkType="Company"&gt;KuDOS&lt;/ulink&gt;, was developing vistusertib (AZD-2014),  an mTOR inhibitor (TORC1, TORC2),   for the potential oral treatment of solid and hematological tumors,  including breast and squamous non-small cell lung cancer (NSCLC), relapsed small cell lung cancer (SCLC)    and lymphoma [&lt;ulink linkID="642815" linkType="Reference"&gt;642815&lt;/ulink&gt;], [&lt;ulink linkID="648480" linkType="Reference"&gt;648480&lt;/ulink&gt;], [&lt;ulink linkID="893305" linkType="Reference"&gt;893305&lt;/ulink&gt;], [&lt;ulink linkID="1384217" linkType="Reference"&gt;1384217&lt;/ulink&gt;], [&lt;ulink linkID="1669608" linkType="Reference"&gt;1669608&lt;/ulink&gt;], [&lt;ulink linkID="1759706" linkType="Reference"&gt;1759706&lt;/ulink&gt;],   [&lt;ulink linkID="1918009" linkType="Reference"&gt;1918009&lt;/ulink&gt;], [&lt;ulink linkID="2011763" linkType="Reference"&gt;2011763&lt;/ulink&gt;].  By September 2016,  the drug had been made available for partnering with academics for clinical and  preclinical development in other indications or as a research tool through AstraZeneca's Open Innovation program [&lt;ulink linkID="1804345" linkType="Reference"&gt;1804345&lt;/ulink&gt;]. By September 2018,  AstraZeneca had discontinued the development of vistusertib for strategic purposes, including the availability of approved drugs using the mTOR pathway [&lt;ulink linkID="2091988" linkType="Reference"&gt;2091988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, a phase II trial was initiated in  metastatic breast cancer   [&lt;ulink linkID="1615088" linkType="Reference"&gt;1615088&lt;/ulink&gt;].  In June 2015, a phase IIa trial was initiated for NSCLC [&lt;ulink linkID="1669608" linkType="Reference"&gt;1669608&lt;/ulink&gt;]. In October 2015, a  phase II trial  was initiated relapsed or refractory diffuse large B-cell lymphoma (DLBCL)  [&lt;ulink linkID="1759706" linkType="Reference"&gt;1759706&lt;/ulink&gt;]; in December 2017, clinical data were presented [&lt;ulink linkID="2002111" linkType="Reference"&gt;2002111&lt;/ulink&gt;].  In SeptemberÂ  2016, a phase II study was initiated for meningioma [&lt;ulink linkID="1797253" linkType="Reference"&gt;1797253&lt;/ulink&gt;]. In April 2017,  a phase II study was planned  to begin  in  patients  with  relapsed SCLC 'later that month'   [&lt;ulink linkID="1918009" linkType="Reference"&gt;1918009&lt;/ulink&gt;]. February 2018, a phase II trial of selumetinib in combination with vistusertib was to begin in patients with unresectable or metastatic neurofibromatosis 1 associated or sporadic malignant peripheral nerve sheath tumors in May 2018 [&lt;ulink linkID="2042808" linkType="Reference"&gt;2042808&lt;/ulink&gt;]. In February 2015, a phase I trial for prostate cancer   was initiated [&lt;ulink linkID="1615083" linkType="Reference"&gt;1615083&lt;/ulink&gt;], in February 2017, preliminary data were presented [&lt;ulink linkID="1904656" linkType="Reference"&gt;1904656&lt;/ulink&gt;].  In July 2017, a phase I study of vistusertib + &lt;ulink linkID="89714" linkType="Drug"&gt;acalabrutinib&lt;/ulink&gt; in patients with relapsed/refractory DLBCL and Richter syndrome began  [&lt;ulink linkID="1988579" linkType="Reference"&gt;1988579&lt;/ulink&gt;]. By September 2018,  AstraZeneca had discontinued the development of vistusertib for strategic purposes, including the availability of approved drugs using the mTOR pathway [&lt;ulink linkID="2091988" linkType="Reference"&gt;2091988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, a phase II study was initiated in metastatic renal cell cancer    [&lt;ulink linkID="1384217" linkType="Reference"&gt;1384217&lt;/ulink&gt;];  this study was terminated in May 2014 on recommendation of the  Independent Data Monitoring Committee [&lt;ulink linkID="1615083" linkType="Reference"&gt;1615083&lt;/ulink&gt;]; in November 2015, negative data were presented [&lt;ulink linkID="1713587" linkType="Reference"&gt;1713587&lt;/ulink&gt;]. No further development has been reported and it is presumed development in this setting was discontinued.&lt;/para&gt;&lt;para&gt;AstraZeneca, following its acquisition of KuDOS,  is also investigating  &lt;ulink linkID="49302" linkType="Drug"&gt;ATM kinase inhibitors&lt;/ulink&gt; and &lt;ulink linkID="33578" linkType="Drug"&gt;DNA-PK inhibitors&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Diffuse large B-cell lymphoma&lt;/subtitle&gt;In October 2015, a non-randomized, open-label phase II trial (&lt;ulink linkID="259278" linkType="Protocol"&gt;NCT02752204&lt;/ulink&gt;; RG_14-212; TORCH) was initiated in the UK in patients (n = 36) with relapsed or refractory diffuse large B-cell lymphoma. The trial was expected to complete in November 2018  [&lt;ulink linkID="1759706" linkType="Reference"&gt;1759706&lt;/ulink&gt;]. In December 2017, clinical data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. Across 9 centers, a total of 30 and 6 patients were enrolled to single-agent first stage and rituximab-combination second stage, respectively. A total of 5.6% of patients achieved partial remission, while complete remission was not achieved; and stable disease was observed in 19.4% of patients. The median progression-free survival was 1.9 months. In patients, the median overall survival was 4.6 months. In responding patients, the median duration of response was 57 days. Fatigue, mucositis, diarrhea and nausea were the most common adverse events [&lt;ulink linkID="2002111" linkType="Reference"&gt;2002111&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Squamous non-small cell lung cancer&lt;/subtitle&gt;In DecemberÂ 2017,  an open-label, multicenter, parallel group, umbrella phase II trial (&lt;ulink linkID="318692" linkType="Protocol"&gt;NCT03334617&lt;/ulink&gt;; D6185C00001; 2017-002208-28; 119833; HUDSON) was initiated in  Canada and South Korea, in patients (expected n = 200) with  metastatic NSCLC, to assess the efficacy, safety and tolerability of multiple treatment arms  with drugs like  vistusertib, olaparib, &lt;ulink linkID="81193" linkType="Drug"&gt;durvalumab&lt;/ulink&gt;, &lt;ulink linkID="69609" linkType="Drug"&gt;AZD-9150&lt;/ulink&gt; and &lt;ulink linkID="84665" linkType="Drug"&gt;AZD-6738&lt;/ulink&gt;. At that time, the trial was yet to be initiated in US, Austria, France, Germany and Israel  and was expected to complete in NovemberÂ 2020 [&lt;ulink linkID="1996527" linkType="Reference"&gt;1996527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, an open-label, non-randomized, single group assignment, multicenter, phase IIa trial (&lt;ulink linkID="225911" linkType="Protocol"&gt;NCT02403895&lt;/ulink&gt;; D2274C00001), was initiated in patients (expected n = 40) with NSCLC in the US and  Germany, with the trial completion in June 2017. By July 2015, the trial had been initiated in Spain [&lt;ulink linkID="1669608" linkType="Reference"&gt;1669608&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2015, an open-label, non-randomized, multi-drug, genetic marker-directed, non-comparative, multicenter, multi-arm, phase II study (&lt;ulink linkID="266967" linkType="Protocol"&gt;NCT02664935&lt;/ulink&gt;; RG_14-072; 2014-000814-73; ISRCTN38344105) in patients (expected n = 620) with NSCLC, was initiated in UK. At that time, the trial was expected to complete in March 2018 [&lt;ulink linkID="1785021" linkType="Reference"&gt;1785021&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In July 2013, plans were being made to evaluate the agent in high-risk prostate cancer patients in preclinical  and early-phase clinical studies [&lt;ulink linkID="1449862" linkType="Reference"&gt;1449862&lt;/ulink&gt;]. In February 2014, an open-label, phase I trial (&lt;ulink linkID="173916" linkType="Protocol"&gt;NCT02064608&lt;/ulink&gt;; CANCAP02,Â 2014-000214-56) was planned to start in June 2014 to investigate the pharmacodynamic biomarker effects ofÂ vistusertib in men with high risk prostate cancer prior to radical prostatectomy (RP). At that time, the trial was expected to complete in September 2015; in February 2015, the trial was initiated in patients (expected n = 20). At that time, the trial was expected to complete in  October 2017 [&lt;ulink linkID="1615083" linkType="Reference"&gt;1615083&lt;/ulink&gt;]. In February 2017, preliminary data were presented at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, FL. Immunohistochemistry showed mTOR pathway inhibition with reduced tumor cell proliferation in vistusertib treated patients (primary objective). Mean plasma concentration of vistusertib on the day of RP and 6 to 8 h post dose was 648 and 484 ng/ml, respectively. After two weeks of vistusertib treatment, 4 of 16 evaluable patients had PSA fall [&lt;ulink linkID="1904656" linkType="Reference"&gt;1904656&lt;/ulink&gt;]. In June 2018, further clinical data were presented at the 54th ASCO Annual Meeting in Chicago, IL. Grade 3 adverse events (AEs) including increased  ALT, hypertension, low lymphocyte count, oral mucositis, rash (macula-popular), and urinary tract infection were reported in 13, 13, 38, 13, 13 and 13% of patients, respectively. Overall, 101 drug related AEs were reported (including 66, 26 and 8% grade 1, 2 and 3, respectively) (secondary objective) [&lt;ulink linkID="2039797" linkType="Reference"&gt;2039797&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic renal cancer&lt;/subtitle&gt;In February 2013, an open-label, randomized, phase II study (&lt;ulink linkID="110431" linkType="Protocol"&gt;NCT01793636&lt;/ulink&gt;; 008424 QM) was initiated to compare the  safety and efficacy of  vistusertib with &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt; in patients (estimated n = 122) with advanced metastatic renal cancer and progression on VEGF-targeted therapy    [&lt;ulink linkID="1384217" linkType="Reference"&gt;1384217&lt;/ulink&gt;]. In February 2015, data  presented form 40 evaluable patients that showed progression free survival (PFS) in vistusertib treatment  to be inferior to everolimus (2 versus 5.8 months, respectively), but with  good tolerability. Progression of disease as a best response was higher for vistusertib than everolimus (65% versus 18%). Grade 3 to 4 adverse events occurred with 30 and 59% of patients treated with vistusertib and everolimus,  respectively. The trial was stopped in May 2014 [&lt;ulink linkID="1637903" linkType="Reference"&gt;1637903&lt;/ulink&gt;]. In November 2015, further clinical data were presented from 49 patients at the 11th NCRI Cancer Conference in Liverpool, UK. PFS (primary endpoint) was 1.8 and 4.6 months, respectively, for AZD-2014 and everolimus groups. Overall, the PFS and overall survival rates were less in the AZD-2014 group  compared with everolimus [&lt;ulink linkID="1713587" linkType="Reference"&gt;1713587&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic breast cancer&lt;/subtitle&gt;In December 2015, a randomized, double-blind, multicenter, dose finding/extension, phase I/II trial (&lt;ulink linkID="245421" linkType="Protocol"&gt;NCT02599714&lt;/ulink&gt;; D2270C00020; BRE 253; PASTOR) began in the US and UK to assess the triplet combination of vistusertib in combination with &lt;ulink linkID="10271" linkType="Drug"&gt;palbociclib&lt;/ulink&gt; on a background of hormonal therapy (&lt;ulink linkID="3313" linkType="Drug"&gt;fulvestrant&lt;/ulink&gt;) in postmenopausal women (expected n = 228) with locally advanced or metastatic estrogen receptor-positive advanced or metastatic breast cancer. The trial would comprise of three parts: part A would identify the maximum tolerated dose of the triplet combination; part B would consist of  3 single-arm dose expansion groups to further characterize safety, tolerability, PK, drug-drug interaction and preliminary efficacy; and  part C would assess the efficacy of the triplet combination in a double-blind, placebo-controlled, stratified, parallel group extension. The primary endpoint was PFS at approximately 16 months. In October 2016, the trial was expected to complete in August 2019Â [&lt;ulink linkID="1879323" linkType="Reference"&gt;1879323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, a randomized, open-label, phase II (&lt;ulink linkID="208315" linkType="Protocol"&gt;NCT02216786&lt;/ulink&gt;; 009175QM) of  &lt;ulink linkID="3313" linkType="Drug"&gt;fulvestrant&lt;/ulink&gt; in combination with vistusertib or &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt;Â or alone in estrogen receptor-positive advanced or metastatic breast cancer patients (expected n = 300) was initiated in the UK. At that time, the trial was expected to complete in October 2015 [&lt;ulink linkID="1615088" linkType="Reference"&gt;1615088&lt;/ulink&gt;]. In June 2015, the protocol was approved in Korea [&lt;ulink linkID="1671541" linkType="Reference"&gt;1671541&lt;/ulink&gt;].  In December 2017, clinical data were presented at the 40th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. Median progression free survival (PFS; primary endpoint) was 4.6, 7.5, 7.6, 12.2 months in patients assigned to fulvestrant, fulvestrant + vistusertib (continued), fulvestrant + vistusertib (intermittent) and fulvestrant + everolimus, respectively. There was no significant difference between the patients assigned to fulvestrant + vistusertib (continued), and fulvestrant (hazard ratio 0.87; log-rank p = 0.42); fulvestrant + vistusertib (intermittent) and fulvestrant (HR 0.78; log-rank p = 0.16); and fulvestrant + vistusertib (continued) and fulvestrant + vistusertib (intermittent) (HR 1.11; log-rank p = 0.52) [&lt;ulink linkID="1989798" linkType="Reference"&gt;1989798&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2014, a non-randomized, open-label, phase Ib/II trial (&lt;ulink linkID="207615" linkType="Protocol"&gt;NCT02208375&lt;/ulink&gt;; 2013-0784, NCI-2014-01973) of vistusertibÂ in combination wih &lt;ulink linkID="16063" linkType="Drug"&gt;olaparib&lt;/ulink&gt;Â and &lt;ulink linkID="69095" linkType="Drug"&gt;AZD-5363&lt;/ulink&gt;Â in combination with olaparib was initiated in the US in patients (expected n 150) with recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer. At that time, the trial was expected to complete in November 2020 [&lt;ulink linkID="1615078" linkType="Reference"&gt;1615078&lt;/ulink&gt;]. In June 2018, clinical data were presented at the 54th ASCO Annual Meeting in Chicago, IL. In continuous arm, olaparib 200 mg, bid and vistusertib 50 mg, bid was considered as the recommended phase II dose (RP2D). In intermittent arm, olaparib 300 mg, bid and vistusertib 100 mg, bid was considered as the RP2D. In 22 endometrial cancer patients, the RR was 27%, and CBR was 50%. In 25 ovarian cancer patients, the RR was 20%, and CBR was 68%. In 20 breast cancer patients, the RR was 6%, and CBR was 12% [&lt;ulink linkID="2039910" linkType="Reference"&gt;2039910&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2012, an open-label, phase I study (&lt;ulink linkID="87733" linkType="Protocol"&gt;NCT01597388&lt;/ulink&gt;; D2270C00005; BRE-196) was initiated in the US in patients with ER+ advanced metastatic breast cancer (expected n = 70), to assess the safety, pharmacokinetics and preliminary efficacy of vistusertib in combination with fulvestrant. At that time, the study was scheduled to complete in November 2013 [&lt;ulink linkID="1295543" linkType="Reference"&gt;1295543&lt;/ulink&gt;]. In June 2014, the study was expected to complete in the fourth quarter of 2014 [&lt;ulink linkID="1582865" linkType="Reference"&gt;1582865&lt;/ulink&gt;]. In December 2014, clinical data were presented at the 37th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. Clinical benefit rate (complete response + partial response + stable disease) was 46, 33, 29 and 42% in the vistusertib 50 and 35 mg bid, 100 and 75 mg qd cohorts, respectively. The recommended phase II dose was found to be 50 mg bid  [&lt;ulink linkID="1616578" linkType="Reference"&gt;1616578&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 52nd ASCO meeting in Chicago, IL. Best overall responses including partial response-confirmed, partial response-unconfirmed, stable disease, and progressive disease  were observed in 5, 2, 12, and 6 patients in continous dosing group; 2, 1, 4, and 2 patients in continous recommended phase II dose ((RP2D) 50 mg bid) group; 5, 4, 19, and 8 patients in the intermittent dosing group; and 3, 3, 16, and 7 patients in the intermittent RP2D (125 mg day 1 and 2 fed and fasted) group, respectively. Overall response rate, confirmed and unconfirmed response rate, clinical benefit rate at 24 weeks, progression-free after &amp;gt; 5 cycles, and progression-free after &amp;gt;/= 10 cycles were 23, 33, 43, and 20% in continous dosing group; 27, 36, 45, and 18% in continous RP2D group; 20, 30, 43, and 20% in the intermittent dosing group; and 23, 30, 41, and 20% in the intermittent RP2D group, respectively. In 23, 0, 6, and 2; 1, 0, 1, and 0; 3, 2, 11, and 3; and 1, 2, 9, and 2 fulvestrant pretreated patients in continous dosing,   in continous RP2D, intermittent dosing, and in the intermittent RP2D groups, best overall responses including partial response-confirmed, partial response-unconfirmed, stable disease, and progressive disease , respectively were observed. Overall response rate, confirmed and unconfirmed response rate, clinical benefit rate at 24 weeks, progression-free after &amp;gt; 5 cycles, and progression-free after &amp;gt;/= 10 cycles were 23, 23, 36, 46, and 15; 33, 33, 67, 67, and 33; 16, 26, 32, 47, and 26; and 7, 21, 29, 50, and 21% in continous dosing,   in continous RP2D, intermittent dosing, and in the intermittent RP2D groups, respectively [&lt;ulink linkID="1767393" linkType="Reference"&gt;1767393&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastric cancer&lt;/subtitle&gt;In June 2017, results from VIKTORY study evaluating vistusertib (AZD-2014)/paclitaxel in RICTOR amplification (+) patients with metastatic gastric cancer were presented at the 53rd ASCO meeting in Chicago, IL. Patient derived cells from a gastric cancer harboring RICTOR amplification showed sensitivity to vistusertib [&lt;ulink linkID="1931865" linkType="Reference"&gt;1931865&lt;/ulink&gt;], [&lt;ulink linkID="1928587" linkType="Reference"&gt;1928587&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, a phase II trial (&lt;ulink linkID="229946" linkType="Protocol"&gt;NCT02449655&lt;/ulink&gt;) of vistusertibÂ plus paclitaxel was initiated in Korean patients with biomarker negative (PIK3CA/MEK/RAS/TP53/MET) advanced gastric adenocarcinoma  as a second-line chemotherapy [&lt;ulink linkID="1671541" linkType="Reference"&gt;1671541&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Meningioma&lt;/subtitle&gt;In July 2016, a phase II 	single arm study (&lt;ulink linkID="265471" linkType="Protocol"&gt;NCT02831257&lt;/ulink&gt;; 15-590) of AZD-2014Â was planned to begin in neurofibromatosis 2 patients (expected n = 18) with progressive or symptomatic meningiomas in the US. At that time, the study was to be completed in November 2024. The primary endpoint would be the radiographic response rate at 24 months [&lt;ulink linkID="1797253" linkType="Reference"&gt;1797253&lt;/ulink&gt;], [&lt;ulink linkID="1797255" linkType="Reference"&gt;1797255&lt;/ulink&gt;]. In September 2016, the study was initiated [&lt;ulink linkID="1797253" linkType="Reference"&gt;1797253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Small cell lung cancer&lt;/subtitle&gt;In April 2017, a single-arm, multicenter, phase II study (&lt;ulink linkID="294474" linkType="Protocol"&gt;NCT03106155&lt;/ulink&gt;; 2017-01-003; SUKSES-D) was planned in the UK 'later that month' in patients (expected n = 28) with relapsed small cell lung cancer harboring RICTOR amplification to examine the efficacy of vistusertib monotherapy. At that time, the trial was to complete in June 2019 [&lt;ulink linkID="1918009" linkType="Reference"&gt;1918009&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Malignant peripheral nerve sheath tumors /neurofibromatosis 1/Neurofibromatosis 1&lt;/subtitle&gt;In February 2018, &lt;ulink linkID="1038106" linkType="Company"&gt;Sarcoma Alliance for Research through Collaboration&lt;/ulink&gt; planned to initiate a Simon's two-stage phase II trial (&lt;ulink linkID="329223" linkType="Protocol"&gt;NCT03433183&lt;/ulink&gt;; SARC031; CDMRP-NF150092) of selumetinib in combination with vistusertib to determine the safety and clinical benefit in patients with unresectable or metastatic neurofibromatosis 1 associated or sporadic malignant peripheral nerve sheath tumors in May 2018, in collaboration with &lt;ulink linkID="1128406" linkType="Company"&gt;United States Department of Defense&lt;/ulink&gt; and AstraZeneca. The primary endpoint was clinical benefit rate. At that time, the study was expected to complete in September 2021 [&lt;ulink linkID="2042808" linkType="Reference"&gt;2042808&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In June 2017, clinical data from an open label, dose escalation, phase Ib/IIa study (TORCMEK; &lt;ulink linkID="244846" linkType="Protocol"&gt;NCT02583542&lt;/ulink&gt;) which evaluated the optimal doses and schedule of vistusertib and &lt;ulink linkID="28972" linkType="Drug"&gt;selumetinib&lt;/ulink&gt; in patients with advanced cancerswere presented at the 53rd ASCO meeting in Chicago, IL Separate MTDs were determined for intermittent (I3C) and continuous schedules (C2C); and 13C schedule (vistusertib 125 mg 2 days on , 2 days off + selumetinib 75 mg qd) was selected as recommended phase 2 dose for expansion cohorts.  Adverse events were in keeping with established single agent safety profiles. Preliminary anti-tumor efficacy was observed [&lt;ulink linkID="1931758" linkType="Reference"&gt;1931758&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;âIn December 2017, it was reported at the 59th ASH Annual Meeting and Exposition in Atlanta, GA that a phase I study (&lt;ulink linkID="303854" linkType="Protocol"&gt;NCT03205046&lt;/ulink&gt;) of vistusertib + &lt;ulink linkID="89714" linkType="Drug"&gt;acalabrutinib&lt;/ulink&gt; in patients with relapsed/refractory DLBCL and Richter syndrome was opened for accrual in July 2017 [&lt;ulink linkID="1988579" linkType="Reference"&gt;1988579&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, clinical data from an open-label, multicenter, first-in-man, ascending dose, phase I study which evaluated the pharmacokinetics, safety and tolerability of &lt;ulink linkID="84805" linkType="Drug"&gt;AZD-8186&lt;/ulink&gt; alone and in combination with AZD-2014 or &lt;ulink linkID="77813" linkType="Drug"&gt;abiraterone acetate&lt;/ulink&gt; in 70 patients with cancer  were presented at the 28th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Munich, Germany. Patients in the part-A (dose finding) and part B (expansion cohorts) received AZD-8186 (30, 60, 120, 180, 240, 300 or 360 mg dose, bid continuous, bid 5 days on/2 days off (5/2) or bid 2 days on/5 days off (2/5)) as monotherapy; and in part C and D, patients received AZD-8186 in combination with abiraterone acetate or AZD-2014 (100 mg), respectively. AZD-8186 (single dose) was rapidly absorbed with Tmax of around 1.5 h. After multiple doses, the exposure of AZD-8186 at steady state was dose proportional. Radiological partial response was achieved in two patients, and in a patient with PTEN deficient KRAS mutant colorectal cancer (AZD-8186 120 mg, bid 2/5), partial response was observedÂ [&lt;ulink linkID="1878105" linkType="Reference"&gt;1878105&lt;/ulink&gt;].     In June 2017, further clinical data (&lt;ulink linkID="142862" linkType="Protocol"&gt;NCT01884285&lt;/ulink&gt;) from 87 patients were presented at the 53rd ASCO meeting in Chicago, IL. Similar pharmacokinetics were observed at different dosing schedules. Grade 3 or higher TEAEs were reported in 27 patients; the ALT increases, AST increased, diarrhea, vomiting and fatigue were the most common. DLTs including pyrexia, colitis/diarrhea, skin rash and chills were observed in seven patients; all rapidly resolved with discontinuation and/or standard management. Treatment-related deaths were not observed. At that time, a dose of 120 mg on the 5/2 schedule was under investigation for the combination arms and recruitment was ongoing  [&lt;ulink linkID="1932367" linkType="Reference"&gt;1932367&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2015, clinical data were presented from a phase I study in 67 patients at the 106th AACR meeting in Philadelphia, PA. In the continuous schedule, 43 patients were treated in four cohorts; 50 mg bid (n = 13), 35 mg bid (n = 6), 100 mg qd (n = 10) and 75 mg qd (n= 14). In the intermittent schedule 23 patients were treated on days1 and 2 (2 days out of 7) per week in 2 cohorts: 170 mg bid (n = 8) and 125 mg bid (n = 15). Progressive disease, partial response-confirmed, partial response-unconfirmed, stable disease and clinical benefit were reported in 5, 5, 2, 26 and 20 patients, respectively, in the continuous schedule and in 4, 3, 3, 11 and 8 patients, respectively, in the intermittent schedule [&lt;ulink linkID="1649671" linkType="Reference"&gt;1649671&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, an open-label, multicentre, non-randomized, singleÂ groupÂ assignment,  phase I trial (&lt;ulink linkID="225208" linkType="Protocol"&gt;NCT02398747&lt;/ulink&gt;; D2270C00008) was planned to be initiated in  Japan,  in patients (expected n = 12) with advanced solid malignancies, to assess the safety and tolerability of  vistusertib. At that time, the trial was expected to complete in September 2016 [&lt;ulink linkID="1645508" linkType="Reference"&gt;1645508&lt;/ulink&gt;].Â Later that month, the trial was initiated [&lt;ulink linkID="1645508" linkType="Reference"&gt;1645508&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, clinical data were presented from a dose escalation, open-label, multi-centre, phase I TAX-TORC trial at the 39th European Society for Medical Oncology congress in Madrid Spain. Patients were administered vistusertib bid for 3 days on and 4 days off (3/7 schedule) or 2 days on and 5 days off (2/7 schedule) and on the same day, fixed dose of weekly paclitaxel (80 mg/m(2)). Overall, three patients had dose limiting toxicities (DLT) of grade 3 fatigue and mucositis at 75 mg bid of vistusertib (3/7 schedule) and two patients DLT of grade 3 rash at 100 mg bid of vistusertib. AUC last, Cmax and t1/2 lambda values were estimated to be 2090.48 ng.hr/ml, 578.89 ng/ml and 3.31 hr, respectively for 25 mg dose level; 2821.58 ng.hr/ml, 926.8 ng/ml and 1.97 hr, respectively for 50 mg dose level; 10259.1 ng.hr/ml, 1985.29 ng/ml and 3.15 hr, respectively for 75 mg dose level [&lt;ulink linkID="1597506" linkType="Reference"&gt;1597506&lt;/ulink&gt;]. In December 2016, further clinical data were presented at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria. Fatigue (59%), skin rash (48%), diarrhea (41%), anorexia/weight loss (35%), neuropathy (35%), and oral thrush (35%) or alopecia (46%), anemia (46%), fatigue (42%), diarrhea (29%), nausea (29%) and neuropathy (29%) were the most frequently reported toxicities in vistusertib 50 or 25 mg groups, respectively. Overall response rates were 38 and 15% in vistusertib 25 (tolerated dose) or 50 mg groups, respectively. In 25 mg cohort, the progression free survival of patients was 3.9 months; treatment was ongoing in seven patients.Â  Overall, vistusertib (25 mg) was found to be well tolerated and safe [&lt;ulink linkID="1882499" linkType="Reference"&gt;1882499&lt;/ulink&gt;]. In March 2017, data from &lt;ulink linkID="205232" linkType="Protocol"&gt;NCT02193633&lt;/ulink&gt; study of patients with squamous-NSCLC, high grade serous ovarian cancer and endometrial cancer were presented at the 15th International TAT congress in Paris, France. In the vistusertib 50 mg cohort, AUC was 2821.6 ng.h/ml, Cmax was 926 ng/ml and t1/2 was 3 h. Multiple responses were observed in the dose escalation phase of study, particularly in squamous-NSCLC, high grade serous ovarian cancer and endometrial cancer. Recommended phase II dose was determined as paclitaxel (80 mg/m2) and vistusertib (50 mg, bid on days 1 to 3 for 6/7 weeks) based on toxicity, pharmacokinetics and pharmacodynamic evaluation. With median progression free survival (PFS) of 5.5 months, the response rates based on response evaluation criteria in solid tumors was 52% and based on CA125 was 60% in high grade serous ovarian cancer (HGSOC) patients of expansion cohort [&lt;ulink linkID="1907530" linkType="Reference"&gt;1907530&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 53rd ASCO meeting in Chicago, IL. The recommended dose of vistusertib in HGSOC was 50 mg bid 3/7 days, 6/7 weeks and was well tolerated in a pre-treated population. The response rate ranged from 52 to 60% in pre-treated, platinum-resistant population with HGSOC [&lt;ulink linkID="1932151" linkType="Reference"&gt;1932151&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2009, a non-randomized, open-label, phase I study (&lt;ulink linkID="62436" linkType="Protocol"&gt;NCT01026402&lt;/ulink&gt;; D2270C00001; 2009-015244-42) was planned in patients with advanced solid tumors (expected n = 115), to assess the safety, efficacy and pharmacokinetics of vistusertib. By January 2010, the study had commenced, and was expected to be completed by May 2012 [&lt;ulink linkID="1063268" linkType="Reference"&gt;1063268&lt;/ulink&gt;]. In June 2012, data were presented at the 48th ASCO meeting in Chicago, IL. The 2-part study consisting of a dose escalation (Part A) and an expansion (Part B) phase enrolled 54 patients. The most common drug-related adverse events were fatigue (57%), nausea (44%) and mucositis (39%); grade 3 or above adverse events were mainly fatigue (11%) and mucositis (6%). Vistusertib was found to be rapidly absorbed, with an elimination half-life of 3.88 h at the 50-mg  bid dose. The Cmax and AUC values at this dose were 1672 ng/ml and 7365 ngÂ·h/ml, respectively: the 50-mg oral dose was established as the MTD. Partial responses were seen at the 50-mg dose, with stable disease of &amp;gt;/= 8 weeks in 26% of patients.  Phase II studies were being planned  [&lt;ulink linkID="1296534" linkType="Reference"&gt;1296534&lt;/ulink&gt;], [&lt;ulink linkID="1297889" linkType="Reference"&gt;1297889&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In November 2015, clinical data were presented at the 27th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. Patients received AZD-2014 in intermittent (125 mg bid, day 1 and 2) and continuous dosing schedule (50 mg bid). Higher proportions of patients on continuous dosing schedules of AZD-2014 were discontinued treatment due to toxicity. Improved therapeutic index was observed in intermittent dosing schedule when compared with continuous dosing schedules of AZD-2014 [&lt;ulink linkID="1711222" linkType="Reference"&gt;1711222&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;âIn April 2018, in vivo data were presented at the 109th AACR Annual Meeting in Chicago, IL. In a pharmacodynamic study on tumors collected at the end of the in vivo experiment, p-ERK expression in MAPK pathway was decreased by AZD-2014 either alone or in combination with selumetinib. In uveal melanoma patient-derived xenograft models, selumetinib + AZD-2014 was more effective [&lt;ulink linkID="2022139" linkType="Reference"&gt;2022139&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2017, preclinical data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. Combined inhibition of BTK (&lt;ulink linkID="89714" linkType="Drug"&gt;acalabrutinib&lt;/ulink&gt;) and mTOR (vistusertib) resulted in synergistic and durable anti-tumor effects in both in vitro and in vivo DLBCL models  [&lt;ulink linkID="1988579" linkType="Reference"&gt;1988579&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In  December 2017, preclinical data were presented at the 40th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. The combination of vistusertib with olaparib plus &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; demonstrated increased effectiveness in triple-negative breast cancer cells harboring BRCA1 and PTEN-null mutations [&lt;ulink linkID="1989834" linkType="Reference"&gt;1989834&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. In MCF7 cells, combination treatment with palbociclib and vistusertib resulted in complete growth arrest. In MCF76 cells, palbociclib + vistusertib showed sustained inhibition of proliferation. . In MCF7 xenograft male SCID mice, combination treatment with vistusertib (10 mg/kg, bid, po, 2 days on/ 5 days off), palbociclib (50 mg/kg, qd, po) and fulvestrant (5 mg/kg/ week, sc) resulted in tumor regression [&lt;ulink linkID="1989840" linkType="Reference"&gt;1989840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  November 2016, preclinical data were presented at the 12th NCRI Cancer Conference in Liverpool, UK. In the MCF7 ER+ breast cancer cell line treated with AZD-2014 and palbociclib, a strong anti-proliferative effect was observed both in vitro and in vivo with an enhanced inhibition of the Rb-E2F pathway and increased induction of G1 cell cycle arrest. In vivo tumor regression was observed with triple combination of AZD-2014, palbociclib and endocrine therapy, which had sustained effect even following treatment withdrawal [&lt;ulink linkID="1880998" linkType="Reference"&gt;1880998&lt;/ulink&gt;]. Further data were presented at the same conference. Increased depth and/or time of PI3K pathway suppression, enhanced impact on metabolic pathways, and improved efficacy was observed with combining AZD-8186 with vistusertib, an mTORC1/2 inhibitor [&lt;ulink linkID="1881000" linkType="Reference"&gt;1881000&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. AZD-2014 was found to be well tolerated with no overt toxicity following a short treatment. The combination of AZD-2014 and castration significantly reduced tumor volume and increased proliferation of CD3+ and CD8+ cells. In a genetically engineered mouse model of prostate cancer, the combination of AZD-2014 and castration increased infiltration of T cells and macrophages [&lt;ulink linkID="1755688" linkType="Reference"&gt;1755688&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2015,  data were presented at the 27th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. Synergy was observed with AZD-2014 and &lt;ulink linkID="55237" linkType="Drug"&gt;ibrutinib&lt;/ulink&gt; combination in OCI-Ly10 xenograft tumors. In NOD-SCID mice bearing OCI-Ly10 tumors, efficacy and tolerability of AZD-2014 were maintained with intermittent schedule in combination with ibrutinib [&lt;ulink linkID="1711222" linkType="Reference"&gt;1711222&lt;/ulink&gt;]. AZD-2014 significantly inhibited tumor growth when combined with castration. AZD-2014 reduced proliferation and induced apoptosis. AZD-2014 reduced mTORC1 and mTORC2 activity and significantly reduced ratio of total choline to creatine. AZD-2014 was well tolerated with no overt toxicity [&lt;ulink linkID="1711149" linkType="Reference"&gt;1711149&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Â In November 2015, preclinical data were presented at the 11th NCRI Cancer Conference in Liverpool, UK. Vistusertib had cytotoxicity against hematological malignancies, especially in T-cell acute lymphoblastic leukemia cell lines with IC50 value of &amp;lt; 1 microM [&lt;ulink linkID="1709881" linkType="Reference"&gt;1709881&lt;/ulink&gt;], [&lt;ulink linkID="1709884" linkType="Reference"&gt;1709884&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2015, preclinical data were presented at the 250th ACS meeting in Boston, MA. In MCF7 tumor xenograft model, treatment with &lt;ulink linkID="93031" linkType="Drug"&gt;AZD-9496&lt;/ulink&gt; in combination with AZD-2014 resulted in the reduction of tumor growth [&lt;ulink linkID="1681847" linkType="Reference"&gt;1681847&lt;/ulink&gt;].    &lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA. Vistusertib along with &lt;ulink linkID="10271" linkType="Drug"&gt;palbociclib&lt;/ulink&gt; showed a synergistic inhibitory effect on cell growth of breast cancer cell lines and showed  tumor regressions (&amp;gt;105%) in the MCF7 xenograft model [&lt;ulink linkID="1648929" linkType="Reference"&gt;1648929&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2014, vistusertib had been shown to be a potent inhibitor of mTOR kinase with IC50 2.81 nM. In several in vitro models, vistusertib had inhibited downstream targets of both mTORC1 and mTORC2 in a dose- and time-dependent manner. In the MDA-MB-468 cell line, vistusertib had shown IC50 of 78 and 210 nM, for pAKT and pS6, respectively. In xenograft models, vistusertib induced dose-dependent tumor growth inhibition at well tolerated doses [&lt;ulink linkID="1586754" linkType="Reference"&gt;1586754&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012,  data were presented at the AACR annual meeting in Chicago, IL. The efficacy of vistusertib was compared with &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt; in a preclinical model of estrogen receptor positive (ER+) breast cancer. Data showed that vistusertib had a superior growth inhibitory effect particularly against mTORC1 compared with everolimus. In the study, vistusertib disrupted the interaction between elF4E and elF4G by trapping elF4E to 4E-BP1, inhibited the translation initiation complex and decreased overall protein synthesis. Concentration-dependent inhibition of pAKT, S473, pS6, S236/236 and 4E-BP1T37/46 were also observed, and were maintained over 24 h; everolimus decreased pS6 but reactivated AKT due to feedback, and had no effect on 4E-BP1 phosphorylation. Further data showed that vistusertib induced tumor growth inhibition and pharmacodynamic modulation in MCF7 xenografts and was associated with increase in cytotoxicity in very sensitive cell lines, particularly ER+ and HER2+ breast cancer. Additionally, vistusertib  demonstrated antitumor activity against in vitro and in vivo models of resistance to &lt;ulink linkID="44314" linkType="Drug"&gt;tamoxifen&lt;/ulink&gt; and &lt;ulink linkID="3313" linkType="Drug"&gt;fulvestrant&lt;/ulink&gt; hormone therapy; everolimus only showed partial growth inhibition except in ZR75-1/long-term estrogen deprived lines [&lt;ulink linkID="1275190" linkType="Reference"&gt;1275190&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, preclinical data for KU-0063794 were presented at the 241st ACS Meeting in Anaheim, CA. The agent demonstrated good exposure, inhibition of tumor growth and Akt inhibition in mouse models [&lt;ulink linkID="1174505" linkType="Reference"&gt;1174505&lt;/ulink&gt;], [&lt;ulink linkID="1180572" linkType="Reference"&gt;1180572&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, data were presented at the Fourth Anglo-Swedish Medicinal Chemistry Symposium in Lund, Sweden.  From an initial lead with a a pyrido[2,3-d]pyrimidine core (IC50 = 1.04 microM), elaboration of a 7-phenyl substituent led to the identification of KU-0063794 (IC50 = 16 nM) Â which was selective towards ATM, DNA-PK, Vps34 and a panel of 200 other kinases with IC50 values of &amp;gt;10 microM. KU-0063794 showed good activity in a glioblastoma-astrocytoma U87 MG cellular assay with a GI50 value of 0.36 microM and inhibited phosphorylation of pS6 and Akt at 0.1 and 0.5 microM, respectively. Furthermore, in a U87-MG xenograft model in nude mice at 50 mg/kg, KU-0063794 inhibited tumor growth [&lt;ulink linkID="997085" linkType="Reference"&gt;997085&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, preclinical data were presented at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland. KU-0063794 was well tolerated and displayed dose-dependent  anti-tumor activity [&lt;ulink linkID="950654" linkType="Reference"&gt;950654&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data on KU-0063794 were presented at the 99th AACR meeting in San Diego, CA. KU-0063794 was shown to be a  highly selective potent ATP competitive mTOR inhibitor   with an IC50 value of 0.016 microM [&lt;ulink linkID="893305" linkType="Reference"&gt;893305&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="763">Nerve tumor</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="2802">Meningioma</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3521">Neurofibromatosis type I</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2018-09-30T00:00:00.000Z</StatusDate><Source id="2091988" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2016-08-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-05-11T00:00:00.000Z</StatusDate><Source id="1295543" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2014-02-14T00:00:00.000Z</StatusDate><Source id="1615083" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2015-03-10T00:00:00.000Z</StatusDate><Source id="1645508" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2015-06-05T00:00:00.000Z</StatusDate><Source id="1669608" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2013-02-14T00:00:00.000Z</StatusDate><Source id="1384217" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2802">Meningioma</Indication><StatusDate>2016-07-07T00:00:00.000Z</StatusDate><Source id="1797253" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2017-04-04T00:00:00.000Z</StatusDate><Source id="1918009" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2015-10-31T00:00:00.000Z</StatusDate><Source id="1759706" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2802">Meningioma</Indication><StatusDate>2016-09-25T00:00:00.000Z</StatusDate><Source id="1797253" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2015-03-31T00:00:00.000Z</StatusDate><Source id="1785021" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2015-03-29T00:00:00.000Z</StatusDate><Source id="1645508" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2014-01-31T00:00:00.000Z</StatusDate><Source id="1615088" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2015-02-01T00:00:00.000Z</StatusDate><Source id="1615083" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2015-06-05T00:00:00.000Z</StatusDate><Source id="1669608" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-06-04T00:00:00.000Z</StatusDate><Source id="1671541" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3666">Metastatic stomach cancer</Indication><StatusDate>2015-02-28T00:00:00.000Z</StatusDate><Source id="1671541" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-05-31T00:00:00.000Z</StatusDate><Source id="1295543" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2010-01-29T00:00:00.000Z</StatusDate><Source id="1063268" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2017-12-18T00:00:00.000Z</StatusDate><Source id="1996527" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2017-12-18T00:00:00.000Z</StatusDate><Source id="1996527" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1996527" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1996527" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2017-11-07T00:00:00.000Z</StatusDate><Source id="1996527" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3521">Neurofibromatosis type I</Indication><StatusDate>2018-02-14T00:00:00.000Z</StatusDate><Source id="2042808" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="763">Nerve tumor</Indication><StatusDate>2018-02-14T00:00:00.000Z</StatusDate><Source id="2042808" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27874">KuDOS Pharmaceuticals Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-09-28T00:00:00.000Z</StatusDate><Source id="562260" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-12-23T00:00:00.000Z</StatusDate><Source id="642815" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-13173"><Name>mTOR complex 1</Name><SwissprotNumbers/></Target><Target id="PTGT-13174"><Name>mTOR complex 2</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2022923" linkType="reference" linkID="2022923"&gt;2022923&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20550">University of Cambridge</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20607">University of London</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24839">Harvard Medical School</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29469">Cancer Research UK</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H]1CN(C[C@@H](O1)C)c2nc3c(ccc(n3)c4ccc(c(c4)CO)OC)c(n2)N5CCOCC5</Smiles><Smiles>C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC</Smiles></StructureSmiles><Deals><Deal id="145810" title="AstraZeneca to collaborate with Cancer Research UK on three pre-clinical and clinical oncology projects"/><Deal id="145811" title="AstraZeneca to collaborate with University of Cambridge on three pre-clinical and clinical oncology projects"/><Deal id="151301" title="Cambridge University and AstraZeneca to codevelop drugs for neurodegenerative diseases    "/><Deal id="151854" title="QMUL and AstraZeneca to conduct phase II studies to evaluate AZD-2014 combination regimen against standard therapy to treat MANTA"/><Deal id="162584" title="NCI to award Massachusetts General Hospital funding to conduct phase  II trial for AZD-2014 against meningiomas   "/></Deals><PatentFamilies><PatentFamily id="1752141" number="WO-2009050506" title="Combination 059"/><PatentFamily id="2046571" number="WO-2009153597" title="Composition and process - 356"/><PatentFamily id="2475175" number="WO-2008023161" title="2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors"/><PatentFamily id="2553496" number="WO-2013096907" title="Methods and compositions for combination therapy using PI3K/mTOR inhibitors"/><PatentFamily id="2960619" number="WO-2015095329" title="Compositions and methods for treating sarcoma"/><PatentFamily id="3387315" number="WO-2016150396" title="Process of synthesizing substituted pyridine and pyrimidine compound"/><PatentFamily id="3449868" number="US-20160339030" title="Treatment agents for inhibiting HIV and cancer in HIV infected patients"/><PatentFamily id="4145962" number="WO-2018144791" title="Combination of VPS34 inhibitors and mTOR inhibitors"/><PatentFamily id="4495929" number="WO-2019088176" title="Enhancer of effect of antibody-drug conjugate"/><PatentFamily id="700337" number="WO-2007060404" title="Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novus Therapeutics Inc" id="1031349"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Luoxin Pharmaceutical Group Stock Co Ltd" id="1054140"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Maryland" id="20611"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chinese Academy of Sciences" id="23863"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kobe University" id="25421"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>